TY  - JOUR
AU  - Đurić, Petar
AU  - Dimković, Nada
AU  - Schlieper, Georg
AU  - Đurić, Živka
AU  - Pantelić, Milan
AU  - Mitrović, Milica
AU  - Janković, Aleksandar N.
AU  - Milanov, Marko
AU  - Kuzmanović-Pfićer, Jovana
AU  - Floege, Juergen
PY  - 2020
UR  - https://smile.stomf.bg.ac.rs/handle/123456789/2514
AB  - Background. Sodium thiosulphate (NaTS) is mostly used in haemodialysis (HD) patients with calcific uraemic arteriolopathy. This double-blind, randomized, placebo-controlled study assessed the effect of NaTS on progression of cardiovascular calcifications in HD patients. Methods. From 65 screened patients, we recruited 60 patients with an abdominal aorta Agatston calcification score >= 100. Thirty patients were randomized to receive NaTS 25 g/1.73m(2) and 30 patients to receive 100mL of 0.9% sodium chloride intravenously during the last 15 min of HD over a period of 6 months. The primary endpoint was the absolute change of the abdominal aortic calcification score. Results. The abdominal aortic calcification score and calcification volume of the abdominal aorta increased similarly in both treatment groups during the trial. As compared with the saline group, patients receiving NaTS exhibited a reduction of their iliac artery calcification score (-137 +/- 641 versus 245 +/- 755; P = 0.049), reduced pulse wave velocity (9.6 +/- 2.7 versus 11.4 +/- 3.6; P = 0.000) and a lower carotid intima-media thickness (0.77 +/- 0.1 versus 0.83 +/- 00.17; P = .033) and had better preservation of echocardiographic parameters of left ventricular hypertrophy. No patient of the NaTS group developed new cardiac valve calcifications during the trial as compared with 8 of 29 patients in the saline group. By univariate analysis, NaTS therapy was the only predictor of not developing new valvular calcifications. No adverse events possibly related to NaTS infusion were noted. Conclusions. While NaTS failed to retard abdominal aortic calcification progress, it positively affected calcification progress in iliac arteries and heart valves as well as several other cardiovascular functional parameters.
PB  - Oxford Univ Press, Oxford
T2  - Nephrology Dialysis Transplantation
T1  - Sodium thiosulphate and progression of vascular calcification in end-stage renal disease patients: a double-blind, randomized, placebo-controlled study
VL  - 35
IS  - 1
SP  - 162
EP  - 169
DO  - 10.1093/ndt/gfz204
ER  - 

@article{
author = "Đurić, Petar and Dimković, Nada and Schlieper, Georg and Đurić, Živka and Pantelić, Milan and Mitrović, Milica and Janković, Aleksandar N. and Milanov, Marko and Kuzmanović-Pfićer, Jovana and Floege, Juergen",
year = "2020",
abstract = "Background. Sodium thiosulphate (NaTS) is mostly used in haemodialysis (HD) patients with calcific uraemic arteriolopathy. This double-blind, randomized, placebo-controlled study assessed the effect of NaTS on progression of cardiovascular calcifications in HD patients. Methods. From 65 screened patients, we recruited 60 patients with an abdominal aorta Agatston calcification score >= 100. Thirty patients were randomized to receive NaTS 25 g/1.73m(2) and 30 patients to receive 100mL of 0.9% sodium chloride intravenously during the last 15 min of HD over a period of 6 months. The primary endpoint was the absolute change of the abdominal aortic calcification score. Results. The abdominal aortic calcification score and calcification volume of the abdominal aorta increased similarly in both treatment groups during the trial. As compared with the saline group, patients receiving NaTS exhibited a reduction of their iliac artery calcification score (-137 +/- 641 versus 245 +/- 755; P = 0.049), reduced pulse wave velocity (9.6 +/- 2.7 versus 11.4 +/- 3.6; P = 0.000) and a lower carotid intima-media thickness (0.77 +/- 0.1 versus 0.83 +/- 00.17; P = .033) and had better preservation of echocardiographic parameters of left ventricular hypertrophy. No patient of the NaTS group developed new cardiac valve calcifications during the trial as compared with 8 of 29 patients in the saline group. By univariate analysis, NaTS therapy was the only predictor of not developing new valvular calcifications. No adverse events possibly related to NaTS infusion were noted. Conclusions. While NaTS failed to retard abdominal aortic calcification progress, it positively affected calcification progress in iliac arteries and heart valves as well as several other cardiovascular functional parameters.",
publisher = "Oxford Univ Press, Oxford",
journal = "Nephrology Dialysis Transplantation",
title = "Sodium thiosulphate and progression of vascular calcification in end-stage renal disease patients: a double-blind, randomized, placebo-controlled study",
volume = "35",
number = "1",
pages = "162-169",
doi = "10.1093/ndt/gfz204"
}

Đurić, P., Dimković, N., Schlieper, G., Đurić, Ž., Pantelić, M., Mitrović, M., Janković, A. N., Milanov, M., Kuzmanović-Pfićer, J.,& Floege, J.. (2020). Sodium thiosulphate and progression of vascular calcification in end-stage renal disease patients: a double-blind, randomized, placebo-controlled study. in Nephrology Dialysis Transplantation
Oxford Univ Press, Oxford., 35(1), 162-169.
https://doi.org/10.1093/ndt/gfz204

Đurić P, Dimković N, Schlieper G, Đurić Ž, Pantelić M, Mitrović M, Janković AN, Milanov M, Kuzmanović-Pfićer J, Floege J. Sodium thiosulphate and progression of vascular calcification in end-stage renal disease patients: a double-blind, randomized, placebo-controlled study. in Nephrology Dialysis Transplantation. 2020;35(1):162-169.
doi:10.1093/ndt/gfz204 .

Đurić, Petar, Dimković, Nada, Schlieper, Georg, Đurić, Živka, Pantelić, Milan, Mitrović, Milica, Janković, Aleksandar N., Milanov, Marko, Kuzmanović-Pfićer, Jovana, Floege, Juergen, "Sodium thiosulphate and progression of vascular calcification in end-stage renal disease patients: a double-blind, randomized, placebo-controlled study" in Nephrology Dialysis Transplantation, 35, no. 1 (2020):162-169,
https://doi.org/10.1093/ndt/gfz204 . .

TY  - JOUR
AU  - Ašćerić, Radislav
AU  - Dimković, Nada
AU  - Trajković, Goran Z.
AU  - Ristić, Biljana S.
AU  - Janković, Aleksandar N.
AU  - Đurić, Petar
AU  - Ilijevski, Nenad S.
PY  - 2019
UR  - https://smile.stomf.bg.ac.rs/handle/123456789/2410
AB  - BackgroundPeripheral arterial disease (PAD) is common in patients with end-stage renal disease on hemodialysis, but is frequently underdiagnosed. The risk factors for PAD are well known within the general population, but they differ somewhat in hemodialysis patients. This study aimed to determine the prevalence of PAD and its risk factors in patients on hemodialysis.MethodsThis cross-sectional study included 156 hemodialysis patients. Comorbidities and laboratory parameters were analyzed. Following clinical examinations, the ankle-brachial index was measured in all patients. PAD was diagnosed based on the clinical findings, ankle-brachial index  lt 0.9, and PAD symptoms.ResultsPAD was present in 55 of 156 (35.3%; 95% CI, 27.7-42.8%) patients. The patients with PAD were significantly older (6710years vs. 62 +/- 11years, p=0.014), more likely to have diabetes mellitus (p=0.022), and anemia (p=0.042), and had significantly lower serum albumin (p=0.005), total cholesterol (p=0.024), and iron (p=0.004) levels, higher glucose (p=0.002) and C-reactive protein (p lt 0.001) levels, and lower dialysis adequacies (p=0.040) than the patients without PAD. Multivariate analysis showed higher C-reactive protein level (odds ratio [OR], 1.03; 95% confidence interval [CI], 1.00-1.06; p=0.030), vascular access by Hickman catheter (OR, 4.66; 95% CI, 1.03-21.0; p=0.045), and symptoms of PAD (OR, 5.20; 95% CI, 2.60-10.4; p lt 0.001) as independent factors associated with PAD in hemodialysis patients.ConclusionThe prevalence of PAD was high among patients with end-stage renal disease on hemodialysis. Symptoms of PAD, higher C-reactive protein levels, and Hickman vascular access were independent predictors of PAD in patients on hemodialysis.
PB  - BMC, LONDON
T2  - BMC Nephrology
T1  - Prevalence, clinical characteristics, and predictors of peripheral arterial disease in hemodialysis patients: a cross-sectional study
VL  - 20
DO  - 10.1186/s12882-019-1468-x
ER  - 

@article{
author = "Ašćerić, Radislav and Dimković, Nada and Trajković, Goran Z. and Ristić, Biljana S. and Janković, Aleksandar N. and Đurić, Petar and Ilijevski, Nenad S.",
year = "2019",
abstract = "BackgroundPeripheral arterial disease (PAD) is common in patients with end-stage renal disease on hemodialysis, but is frequently underdiagnosed. The risk factors for PAD are well known within the general population, but they differ somewhat in hemodialysis patients. This study aimed to determine the prevalence of PAD and its risk factors in patients on hemodialysis.MethodsThis cross-sectional study included 156 hemodialysis patients. Comorbidities and laboratory parameters were analyzed. Following clinical examinations, the ankle-brachial index was measured in all patients. PAD was diagnosed based on the clinical findings, ankle-brachial index  lt 0.9, and PAD symptoms.ResultsPAD was present in 55 of 156 (35.3%; 95% CI, 27.7-42.8%) patients. The patients with PAD were significantly older (6710years vs. 62 +/- 11years, p=0.014), more likely to have diabetes mellitus (p=0.022), and anemia (p=0.042), and had significantly lower serum albumin (p=0.005), total cholesterol (p=0.024), and iron (p=0.004) levels, higher glucose (p=0.002) and C-reactive protein (p lt 0.001) levels, and lower dialysis adequacies (p=0.040) than the patients without PAD. Multivariate analysis showed higher C-reactive protein level (odds ratio [OR], 1.03; 95% confidence interval [CI], 1.00-1.06; p=0.030), vascular access by Hickman catheter (OR, 4.66; 95% CI, 1.03-21.0; p=0.045), and symptoms of PAD (OR, 5.20; 95% CI, 2.60-10.4; p lt 0.001) as independent factors associated with PAD in hemodialysis patients.ConclusionThe prevalence of PAD was high among patients with end-stage renal disease on hemodialysis. Symptoms of PAD, higher C-reactive protein levels, and Hickman vascular access were independent predictors of PAD in patients on hemodialysis.",
publisher = "BMC, LONDON",
journal = "BMC Nephrology",
title = "Prevalence, clinical characteristics, and predictors of peripheral arterial disease in hemodialysis patients: a cross-sectional study",
volume = "20",
doi = "10.1186/s12882-019-1468-x"
}

Ašćerić, R., Dimković, N., Trajković, G. Z., Ristić, B. S., Janković, A. N., Đurić, P.,& Ilijevski, N. S.. (2019). Prevalence, clinical characteristics, and predictors of peripheral arterial disease in hemodialysis patients: a cross-sectional study. in BMC Nephrology
BMC, LONDON., 20.
https://doi.org/10.1186/s12882-019-1468-x

Ašćerić R, Dimković N, Trajković GZ, Ristić BS, Janković AN, Đurić P, Ilijevski NS. Prevalence, clinical characteristics, and predictors of peripheral arterial disease in hemodialysis patients: a cross-sectional study. in BMC Nephrology. 2019;20.
doi:10.1186/s12882-019-1468-x .

Ašćerić, Radislav, Dimković, Nada, Trajković, Goran Z., Ristić, Biljana S., Janković, Aleksandar N., Đurić, Petar, Ilijevski, Nenad S., "Prevalence, clinical characteristics, and predictors of peripheral arterial disease in hemodialysis patients: a cross-sectional study" in BMC Nephrology, 20 (2019),
https://doi.org/10.1186/s12882-019-1468-x . .

TY  - JOUR
AU  - Donfrid, Branislav
AU  - Lozanče, Olivera B.
AU  - Stefanović, Zvezdan
AU  - Janković, Aleksandar N.
AU  - Dimković, Nada
PY  - 2018
UR  - https://smile.stomf.bg.ac.rs/handle/123456789/2344
AB  - Introduction The autologous radio-cephalic arteriovenous fistula (AVF) is the best vascular access for patients on chronic hemodialysis. In some patients with inadequate blood vessels, it is necessary to create proximal AVF, or arteriovenous grafts. High percentage of primary graft failure is noted in cases where diameters of the brachial artery and the basilic vein are insufficient. The aim of this work was to introduce a new surgical technique for arteriovenous creation in patients with inadequate blood diameter. Case outline The authors have proposed implantation of brachio-basilic polytetrafluoroethylene AV forearm loop graft in two acts. In the first act, the native brachio-basilic AVF was created in the distal region of the arm by side-to-end anastomosis. Three to four weeks after the first act, significant dilatation of brachial artery and basilic vein was noted (confirmed by the use of color duplex sonography technique). During the second act, polytetrafluourethylene graft was implanted by end-to-end anastomosis on the dilated basilica vein. Conclusion AV graft that was created in two acts has sufficient blood flow without early or late complications. Primary patency was 30 months and secondary patency was 50 months. As an original method in the current literature, we recommend it in different clinical settings when there are no better alternatives for vascular access.
AB  - Uvod Autologna radiocefalična arteriovenska fistula je najbolji vaskularni pristup za bolesnike na hemodijalizi. Kod nekih bolesnika sa neadekvatnim krvnim sudovima potrebno je kreirati proksimalnu arteriovensku fistulu ili implantirati arteriovenski graft. Visoki procenat ranog zatajivanja grafta najčešće nastaje usled malog prečnika bazilične vene ili brahijalne arterije. Cilj ovoga rada je bio da prikaže novu hiruršku tehniku za kreiranje arteriovenskog grafta kod bolesnika sa neodgovarajućim dijametrom krvnih sudova. Prikaz bolesnika Urađena je implantacija PTFE grafta u vidu petlje na podlaktici u dva akta. U prvom aktu je u distalnom delu nadlaktice kreirana brahio-bazilična latero-terminalna arteriovenska fistula pod uglom od 90 stepeni. Posle četiri nedelje, kontrolnom doplersonografijom je konstatovano znatno povećanje prečnika bazilične vene i brahijalne arterije. U drugom aktu je bazilična vena poprečno presečena i sa dve temino-terminalne anastomoze u vidu petlje umetnut PTFE graft. Zaključak Ovako kreiran arteriovenski graft u dva akta davao je zadovoljavajući protok krvi bez komplikacija. Primarna funkcionalnost je iznosila 30 meseci, a sekundarna 50 meseci. U dostupnoj literaturi ovakav postupak nije objavljen, a preporučujemo ga kod bolesnika bez drugih mogućnosti za kreiranje vaskularnog pristupa.
PB  - Srpsko lekarsko društvo, Beograd
T2  - Srpski arhiv za celokupno lekarstvo
T1  - Two-stage forearm brachio-basilic loop arteriovenous graft for hemodialysis
T1  - Podlakatni brahio-bazilični arteriovenski graft za hemodijalizu u dva akta
VL  - 146
IS  - 5-6
SP  - 316
EP  - 319
DO  - 10.2298/SARH161228138D
ER  - 

@article{
author = "Donfrid, Branislav and Lozanče, Olivera B. and Stefanović, Zvezdan and Janković, Aleksandar N. and Dimković, Nada",
year = "2018",
abstract = "Introduction The autologous radio-cephalic arteriovenous fistula (AVF) is the best vascular access for patients on chronic hemodialysis. In some patients with inadequate blood vessels, it is necessary to create proximal AVF, or arteriovenous grafts. High percentage of primary graft failure is noted in cases where diameters of the brachial artery and the basilic vein are insufficient. The aim of this work was to introduce a new surgical technique for arteriovenous creation in patients with inadequate blood diameter. Case outline The authors have proposed implantation of brachio-basilic polytetrafluoroethylene AV forearm loop graft in two acts. In the first act, the native brachio-basilic AVF was created in the distal region of the arm by side-to-end anastomosis. Three to four weeks after the first act, significant dilatation of brachial artery and basilic vein was noted (confirmed by the use of color duplex sonography technique). During the second act, polytetrafluourethylene graft was implanted by end-to-end anastomosis on the dilated basilica vein. Conclusion AV graft that was created in two acts has sufficient blood flow without early or late complications. Primary patency was 30 months and secondary patency was 50 months. As an original method in the current literature, we recommend it in different clinical settings when there are no better alternatives for vascular access., Uvod Autologna radiocefalična arteriovenska fistula je najbolji vaskularni pristup za bolesnike na hemodijalizi. Kod nekih bolesnika sa neadekvatnim krvnim sudovima potrebno je kreirati proksimalnu arteriovensku fistulu ili implantirati arteriovenski graft. Visoki procenat ranog zatajivanja grafta najčešće nastaje usled malog prečnika bazilične vene ili brahijalne arterije. Cilj ovoga rada je bio da prikaže novu hiruršku tehniku za kreiranje arteriovenskog grafta kod bolesnika sa neodgovarajućim dijametrom krvnih sudova. Prikaz bolesnika Urađena je implantacija PTFE grafta u vidu petlje na podlaktici u dva akta. U prvom aktu je u distalnom delu nadlaktice kreirana brahio-bazilična latero-terminalna arteriovenska fistula pod uglom od 90 stepeni. Posle četiri nedelje, kontrolnom doplersonografijom je konstatovano znatno povećanje prečnika bazilične vene i brahijalne arterije. U drugom aktu je bazilična vena poprečno presečena i sa dve temino-terminalne anastomoze u vidu petlje umetnut PTFE graft. Zaključak Ovako kreiran arteriovenski graft u dva akta davao je zadovoljavajući protok krvi bez komplikacija. Primarna funkcionalnost je iznosila 30 meseci, a sekundarna 50 meseci. U dostupnoj literaturi ovakav postupak nije objavljen, a preporučujemo ga kod bolesnika bez drugih mogućnosti za kreiranje vaskularnog pristupa.",
publisher = "Srpsko lekarsko društvo, Beograd",
journal = "Srpski arhiv za celokupno lekarstvo",
title = "Two-stage forearm brachio-basilic loop arteriovenous graft for hemodialysis, Podlakatni brahio-bazilični arteriovenski graft za hemodijalizu u dva akta",
volume = "146",
number = "5-6",
pages = "316-319",
doi = "10.2298/SARH161228138D"
}

Donfrid, B., Lozanče, O. B., Stefanović, Z., Janković, A. N.,& Dimković, N.. (2018). Two-stage forearm brachio-basilic loop arteriovenous graft for hemodialysis. in Srpski arhiv za celokupno lekarstvo
Srpsko lekarsko društvo, Beograd., 146(5-6), 316-319.
https://doi.org/10.2298/SARH161228138D

Donfrid B, Lozanče OB, Stefanović Z, Janković AN, Dimković N. Two-stage forearm brachio-basilic loop arteriovenous graft for hemodialysis. in Srpski arhiv za celokupno lekarstvo. 2018;146(5-6):316-319.
doi:10.2298/SARH161228138D .

Donfrid, Branislav, Lozanče, Olivera B., Stefanović, Zvezdan, Janković, Aleksandar N., Dimković, Nada, "Two-stage forearm brachio-basilic loop arteriovenous graft for hemodialysis" in Srpski arhiv za celokupno lekarstvo, 146, no. 5-6 (2018):316-319,
https://doi.org/10.2298/SARH161228138D . .

TY  - JOUR
AU  - Grubiša, Ivana
AU  - Otašević, Petar
AU  - Dimković, Nada
AU  - Nedeljković, Ivana
AU  - Toljić, Boško
AU  - Vučinić, Nada
PY  - 2013
UR  - https://smile.stomf.bg.ac.rs/handle/123456789/1800
AB  - Introduction. Paraoxonase 1 (PON1) is a multifunctional enzyme associated with high-density lipoprotein particles (HDL). It is a cellular antioxidant that hydrolyses oxidized macromolecules, especially low-density lipoproteins (ox-LDL). Because increased oxidative stress is believed to play a crucial role in the initiation and propagation of atherosclerosis, coding (Q192R and L55M) and promoter (C(-107)T) region polymorphisms of pon1 gene, that are responsible for catalytic efficiency, activity and the level of the enzyme, have been of great interest as a potential markers of susceptibility for atherogenesis. Objective. The aim of the study was to assess possible association between these pon1 gene variants and clinical manifestations of the atherosclerosis and oxidative stress. Methods. A total of 60 angiographically documented patients with manifested atherosclerotic disease and 100 control individuals were analyzed. Genomic DNA was isolated from the peripheral blood cells and genotyping was performed using polymerase chain reaction followed by the restriction fragment length polymorphism (PCR-RFLP) analysis. Results No significant difference in allele and genotype frequencies of all three examined polymorphisms was found between the atherosclerotic patients and healthy controls. The obtained results could not support an association of pon1 gene variants with the oxidative stress and atherogenesis. Conclusion. These polymorphisms cannot be considered risk factors of atherosclerosis in Serbian population. A larger study is required in order to establish possible contribution of pon1 variants to atherosclerosis-related cardiovascular diseases.
AB  - Uvod. Paraoksonaza 1 (PON1) je multifunkcionalni enzim koji je vezan za lipoproteine visoke gustine (HDL). To je ćelijski antioksidans koji hidrolizuje oksidovane makromolekule, naročito oksidovane lipoproteine niske gustine (ox-LDL). Smatra se da povišeni oksidativni stres igra ključnu ulogu u inicijaciji i propagaciji ateroskleroze, pa su polimorfizmi u kodirajućem (Q192R i L55M) i promotorskom (C(-107)T) regionu gena pon1, koji su odgovorni za katalitičku efikasnost, aktivnost i nivo enzima, od velikog interesa kao potencijalni markeri osetljivosti na aterogenezu. Cilj rada. Cilj ove studije je bio da se ispita moguća povezanost varijanti gena pon1 i kliničkih manifestacija ateroskleroze i oksidativnog stresa. Metode rada. Analizirano je 60 bolesnika s angiografski dokumentovanim manifestacijama ateroskleroze i 100 zdravih ispitanika. Genomska DNK je izolovana iz ćelija periferne krvi, a genotipizacija je urađena primenom reakcije lančane polimeraze, posle koje je urađena analiza dužine restrikcionih fragmenata (tzv. PCR-RFLP analiza). Rezultati. Učestalosti alela i genotipova tri ispitivana polimorfizma nisu pokazale značajne razlike između ispitanika obolelih od ateroskleroze i zdravih osoba. Dobijeni rezultati ne ukazuju na povezanost analiziranih varijanti gena pon1 i oksidativnog stresa i aterogeneze. Zaključak. Ovi polimorfizmi se ne mogu smatrati faktorima rizika za razvoj ateroskleroze u srpskoj populaciji. Potrebna je studija sa većim brojem ispitanika, kako bi se utvrdio mogući doprinos varijanti gena pon1 na nastanak kardiovaskularnih oboljenja u čijoj osnovi je ateroskleroza.
PB  - Srpsko lekarsko društvo, Beograd
T2  - Srpski arhiv za celokupno lekarstvo
T1  - Genetic polymorphisms of paraoxonase 1 and susceptibility to atherogenesis
T1  - Genetički polimorfizmi paraoksonaze 1 i podložnost aterogenezi
VL  - 141
IS  - 9-10
SP  - 629
EP  - 633
DO  - 10.2298/SARH1310629G
ER  - 

@article{
author = "Grubiša, Ivana and Otašević, Petar and Dimković, Nada and Nedeljković, Ivana and Toljić, Boško and Vučinić, Nada",
year = "2013",
abstract = "Introduction. Paraoxonase 1 (PON1) is a multifunctional enzyme associated with high-density lipoprotein particles (HDL). It is a cellular antioxidant that hydrolyses oxidized macromolecules, especially low-density lipoproteins (ox-LDL). Because increased oxidative stress is believed to play a crucial role in the initiation and propagation of atherosclerosis, coding (Q192R and L55M) and promoter (C(-107)T) region polymorphisms of pon1 gene, that are responsible for catalytic efficiency, activity and the level of the enzyme, have been of great interest as a potential markers of susceptibility for atherogenesis. Objective. The aim of the study was to assess possible association between these pon1 gene variants and clinical manifestations of the atherosclerosis and oxidative stress. Methods. A total of 60 angiographically documented patients with manifested atherosclerotic disease and 100 control individuals were analyzed. Genomic DNA was isolated from the peripheral blood cells and genotyping was performed using polymerase chain reaction followed by the restriction fragment length polymorphism (PCR-RFLP) analysis. Results No significant difference in allele and genotype frequencies of all three examined polymorphisms was found between the atherosclerotic patients and healthy controls. The obtained results could not support an association of pon1 gene variants with the oxidative stress and atherogenesis. Conclusion. These polymorphisms cannot be considered risk factors of atherosclerosis in Serbian population. A larger study is required in order to establish possible contribution of pon1 variants to atherosclerosis-related cardiovascular diseases., Uvod. Paraoksonaza 1 (PON1) je multifunkcionalni enzim koji je vezan za lipoproteine visoke gustine (HDL). To je ćelijski antioksidans koji hidrolizuje oksidovane makromolekule, naročito oksidovane lipoproteine niske gustine (ox-LDL). Smatra se da povišeni oksidativni stres igra ključnu ulogu u inicijaciji i propagaciji ateroskleroze, pa su polimorfizmi u kodirajućem (Q192R i L55M) i promotorskom (C(-107)T) regionu gena pon1, koji su odgovorni za katalitičku efikasnost, aktivnost i nivo enzima, od velikog interesa kao potencijalni markeri osetljivosti na aterogenezu. Cilj rada. Cilj ove studije je bio da se ispita moguća povezanost varijanti gena pon1 i kliničkih manifestacija ateroskleroze i oksidativnog stresa. Metode rada. Analizirano je 60 bolesnika s angiografski dokumentovanim manifestacijama ateroskleroze i 100 zdravih ispitanika. Genomska DNK je izolovana iz ćelija periferne krvi, a genotipizacija je urađena primenom reakcije lančane polimeraze, posle koje je urađena analiza dužine restrikcionih fragmenata (tzv. PCR-RFLP analiza). Rezultati. Učestalosti alela i genotipova tri ispitivana polimorfizma nisu pokazale značajne razlike između ispitanika obolelih od ateroskleroze i zdravih osoba. Dobijeni rezultati ne ukazuju na povezanost analiziranih varijanti gena pon1 i oksidativnog stresa i aterogeneze. Zaključak. Ovi polimorfizmi se ne mogu smatrati faktorima rizika za razvoj ateroskleroze u srpskoj populaciji. Potrebna je studija sa većim brojem ispitanika, kako bi se utvrdio mogući doprinos varijanti gena pon1 na nastanak kardiovaskularnih oboljenja u čijoj osnovi je ateroskleroza.",
publisher = "Srpsko lekarsko društvo, Beograd",
journal = "Srpski arhiv za celokupno lekarstvo",
title = "Genetic polymorphisms of paraoxonase 1 and susceptibility to atherogenesis, Genetički polimorfizmi paraoksonaze 1 i podložnost aterogenezi",
volume = "141",
number = "9-10",
pages = "629-633",
doi = "10.2298/SARH1310629G"
}

Grubiša, I., Otašević, P., Dimković, N., Nedeljković, I., Toljić, B.,& Vučinić, N.. (2013). Genetic polymorphisms of paraoxonase 1 and susceptibility to atherogenesis. in Srpski arhiv za celokupno lekarstvo
Srpsko lekarsko društvo, Beograd., 141(9-10), 629-633.
https://doi.org/10.2298/SARH1310629G

Grubiša I, Otašević P, Dimković N, Nedeljković I, Toljić B, Vučinić N. Genetic polymorphisms of paraoxonase 1 and susceptibility to atherogenesis. in Srpski arhiv za celokupno lekarstvo. 2013;141(9-10):629-633.
doi:10.2298/SARH1310629G .

Grubiša, Ivana, Otašević, Petar, Dimković, Nada, Nedeljković, Ivana, Toljić, Boško, Vučinić, Nada, "Genetic polymorphisms of paraoxonase 1 and susceptibility to atherogenesis" in Srpski arhiv za celokupno lekarstvo, 141, no. 9-10 (2013):629-633,
https://doi.org/10.2298/SARH1310629G . .

TY  - JOUR
AU  - Stanković-Popović, Verica
AU  - Popović, Dragan
AU  - Dimković, Nada
AU  - Maksić, Đoko
AU  - Vasilijić, Saša
AU  - Čolić, Miodrag
AU  - Vučinić, Žarko
AU  - Rađen, Slavica
AU  - Miličić, Biljana
PY  - 2013
UR  - https://smile.stomf.bg.ac.rs/handle/123456789/1774
AB  - Background/Aim. Morbidity and mortality of continous ambulatory peritoneal dialysis (CAPD) patients is still very high. The aim of the study was to evaluate the effects of peritoneal dialysis (PD) solutions (standard vs biocompatible) on long-term patients' and the techique survival. Methods. A total of 42 stable patients on CAPD participated in this crosssectional study. They were prospectively followed-up during the twelve years. Patients with severe anemia (Hb  lt  10 g/L) and malignant disease ware excluded. Twenty one (50%) patients were treated with the standard PD solutions (CAPDP- 1) while the other 21 (50%) were treated with biocompatible PD solutions [(lower level of glucose degradation products, lower concentration of Ca2+ and neutral pH (CAPDP-2)]. All patients were analyzed for a presence of vascular calcification, nutrition status, and parameters of inflammation after 2.5 ± 0.6 years of starting CAPD, and these variables considered in the analysis as risk factors. Results. The patients from the group CAPDP-2 compared to those from the group CAPDP-1 had lower level of high-sensitivity C-reactive protein (hs-CRP) (p = 0.003), and better nutritional status as confirmed by the mid-arm circumference (p = 0.015), and midarm muscle circumference (p = 0.002) and subjective global assessment (p = 0.000). Also, they had lower vascular calcifications as confirmed by intima media thickness (IMT) (p = 0.003), degree of carotid narrowing (p = 0.001) and calcified plaques of common carotid arteries (CCA) (p = 0.008). Kaplan- Meier analysis confirmed better survival of patients from the group CAPDP-2 than those from the group CAPDP-1 (1-, 5-, and 10-year patients survival rate was: 100%, 61.9% and 14.3% for the group CAPDP-1, and 100%, 85.7%, and 52.4% for the group CAPDP-2, respectively; p = 0.0345). The 1-, 5-, and 10-year technique survival rate was: 100%, 71.4%, and 38.1% for the group CAPDP-1, and 100%, 85.7%, and 76.2% for the group CAPDP-2, respectively; (p = 0.0719). Duration of dialysis, serum triglyceride and cardiovascular score (quantitative scoring system consisting of: ejection fraction (EF) of left ventricle  lt  50%; IMT > 1 mm; carotid narrowing degree > 50%, presence of carotid plaques in both common carotide, ischaemic heart disease, cerebrovascular event and peripheral vascular disease with or without amputation) were independent predictors of overall patient survival. Duration of dialysis was only independent predictor of overall technique survival. Conclusion. Although patients treated with biocompatible solutions showed significantly better survival, the role of biocompatibility of CAPD solutions in patients and technique survival have to be confirmed. Namely, multivariate analysis confirmed that duration of dialysis, serum triglyceride and cardiovascular score significantly predicted overall CAPD patients survival, while only duration of dialysis was found to be independent predictor of overall technique survival.
AB  - Uvod/Cilj. Morbiditet i mortalitet bolesnika na kontinuiranoj ambulantnoj peritoneumskoj dijalizi (KAPD) i dalje je neprihvatljivo visok. Cilj rada bio je da se proceni uticaj vrste dijaliznih rasvora (bioinkompatibilni vs biokompatibilni) na višegodišnje preživljavanje bolesnika i same tehnike KAPD. Metode. Ovom studijom preseka sa delimično prospektivnim praćenjem ishoda lečenja obuhvaćeno je ukupno 42 nasumice izabrana, stabilna bolesnika (26 muškaraca i 16 žena) lečena primenom metode KAPD tokom poslednjih 12 godina. Isključeni su bolesnici sa teškom anemijom (Hb  lt 10 g/L) i malignom bolešću. Pri tome, 21 (50%) bolesnika kontinuirano je lečeno bioinkompatibilnim rastvorom za KAPD (kiseli standardni rastvor - ANDY-disc; grupa KAPDB-1), dok je preostalih 21 bolesnik sve vreme bilo na biokompatibilnijem rastvoru za KAPD (neutralni rastvor sa znatno manjom koncentracijom degradacionih produkata glukoze, 1.25 mmol/L Ca i 40 mmol/L laktata - Gambrosol Trio; grupa KAPDB-2). Svim bolesnicima određeni su odabrani parametri hronične inflamacije, malnutricije i ateroskleroze zajedno sa transportnim karakteristikama peritoneumske membrane i rezidualnom bubrežnom funkcijom nakon 2,5 ± 0,6 god od započinjanja KAPD. Svi dobijeni rezultati analizirani su kao potencijalni faktori rizika. Rezultati. Grupa KAPDB-2 u odnosu na KAPDB-1 imala je statistički značajno niže vrednosti serumskog hs-CRP (p = 0,003) i bolje parametre nutritivnog statusa izražene kroz obim nadlaktice (p = 0,015), obim mišića nadlaktice (p = 0,002) i subjektivnu globalnu procenu (p = 0,000) kao i u manjoj meri prisutnu aterosklerozu potvrđeno debljinom intimomedijalnog kompleksa (IMT) (p = 0,003), stepenom suženja karotida (p = 0,001) i prisustvom kalcifikovanih ateromatoznih plakova na karotidnim arterijama (p = 0,008). Kaplan-Meier-ova kriva preživljavanja potvrdila je značajno duže preživljavanje bolesnika u grupi KAPD-2 u odnosu na KAPDB-1 (1-, 5-, i 10-godišnje preživljavanje bolesnika iznosilo je redom: 100%, 61.9% i 14.3% u KAPDB-1, a 100%, 85,7% i 52,4% u KAPDB-2 grupi; p = 0,0345). Stopa 1-, 5-, i 10-godišnjeg preživljavanja metode iznosila je: 100%, 71,4% i 38,1% u KAPDB-1, a 100%, 85,7% i 76,2% u KAPDB-2 grupi (p = 0,0719). Kao nezavisni prediktori opšteg preživljavanja bolesnika na KAPD izdvojili su se: dijalizni staž, nivo serumskih triglicerida i skor kardiovaskularnog morbiditeta (kvantitativni sistem zbrajanja prisutnih sledećih parametara: ejekciona frakcija (EF) leve komore  lt  50%; IMT >1 mm; suženje lumena karotida > 50%; kalcifikovani ateromatozni plakovi na obe karotide; ishemijska bolest srca; cerebrovaskularni događaj i periferna vaskularna bolest sa ili bez gangrene). Kao nezavisan prediktor preživljavanja metode izdvojio se jedino dijalizni staž. Zaključak. Iako su bolesnici na KAPD sa biokompatibilnijim rastvorima pokazali statistički značajno bolje preživljavanje, ne možemo tvrditi da bioinkompatibilnost dijaliznih rastvora predstavlja značajan faktor rizika od preživljavanja bolesnika i same metode lečenja. Naime, multivarijantnom analizom kao prediktori opšteg preživljavanja bolesnika izdvojili su se samo dijalizni staž, nivo serumskih triglicerida i skor kardiovaskularnog morbiditeta, dok se za očuvanje peritoneumske membrane kao nezavisan faktor rizika prikazao samo dijalizni staž.
PB  - Vojnomedicinska akademija - Institut za naučne informacije, Beograd
T2  - Vojnosanitetski pregled
T1  - Influence of peritoneal dialysis solution biocompatibility on long-term survival of patients on continuous ambulatory peritoneal dialysis and the technique itself
T1  - Uticaj biokompatibilnosti rastvora za peritoneumsku dijalizu na višegodišnje preživljavanje bolesnika na kontinuiranoj ambulantnoj peritoneumskoj dijalizi i same metode lečenja
VL  - 70
IS  - 4
SP  - 352
EP  - 362
DO  - 10.2298/VSP1304352S
ER  - 

@article{
author = "Stanković-Popović, Verica and Popović, Dragan and Dimković, Nada and Maksić, Đoko and Vasilijić, Saša and Čolić, Miodrag and Vučinić, Žarko and Rađen, Slavica and Miličić, Biljana",
year = "2013",
abstract = "Background/Aim. Morbidity and mortality of continous ambulatory peritoneal dialysis (CAPD) patients is still very high. The aim of the study was to evaluate the effects of peritoneal dialysis (PD) solutions (standard vs biocompatible) on long-term patients' and the techique survival. Methods. A total of 42 stable patients on CAPD participated in this crosssectional study. They were prospectively followed-up during the twelve years. Patients with severe anemia (Hb  lt  10 g/L) and malignant disease ware excluded. Twenty one (50%) patients were treated with the standard PD solutions (CAPDP- 1) while the other 21 (50%) were treated with biocompatible PD solutions [(lower level of glucose degradation products, lower concentration of Ca2+ and neutral pH (CAPDP-2)]. All patients were analyzed for a presence of vascular calcification, nutrition status, and parameters of inflammation after 2.5 ± 0.6 years of starting CAPD, and these variables considered in the analysis as risk factors. Results. The patients from the group CAPDP-2 compared to those from the group CAPDP-1 had lower level of high-sensitivity C-reactive protein (hs-CRP) (p = 0.003), and better nutritional status as confirmed by the mid-arm circumference (p = 0.015), and midarm muscle circumference (p = 0.002) and subjective global assessment (p = 0.000). Also, they had lower vascular calcifications as confirmed by intima media thickness (IMT) (p = 0.003), degree of carotid narrowing (p = 0.001) and calcified plaques of common carotid arteries (CCA) (p = 0.008). Kaplan- Meier analysis confirmed better survival of patients from the group CAPDP-2 than those from the group CAPDP-1 (1-, 5-, and 10-year patients survival rate was: 100%, 61.9% and 14.3% for the group CAPDP-1, and 100%, 85.7%, and 52.4% for the group CAPDP-2, respectively; p = 0.0345). The 1-, 5-, and 10-year technique survival rate was: 100%, 71.4%, and 38.1% for the group CAPDP-1, and 100%, 85.7%, and 76.2% for the group CAPDP-2, respectively; (p = 0.0719). Duration of dialysis, serum triglyceride and cardiovascular score (quantitative scoring system consisting of: ejection fraction (EF) of left ventricle  lt  50%; IMT > 1 mm; carotid narrowing degree > 50%, presence of carotid plaques in both common carotide, ischaemic heart disease, cerebrovascular event and peripheral vascular disease with or without amputation) were independent predictors of overall patient survival. Duration of dialysis was only independent predictor of overall technique survival. Conclusion. Although patients treated with biocompatible solutions showed significantly better survival, the role of biocompatibility of CAPD solutions in patients and technique survival have to be confirmed. Namely, multivariate analysis confirmed that duration of dialysis, serum triglyceride and cardiovascular score significantly predicted overall CAPD patients survival, while only duration of dialysis was found to be independent predictor of overall technique survival., Uvod/Cilj. Morbiditet i mortalitet bolesnika na kontinuiranoj ambulantnoj peritoneumskoj dijalizi (KAPD) i dalje je neprihvatljivo visok. Cilj rada bio je da se proceni uticaj vrste dijaliznih rasvora (bioinkompatibilni vs biokompatibilni) na višegodišnje preživljavanje bolesnika i same tehnike KAPD. Metode. Ovom studijom preseka sa delimično prospektivnim praćenjem ishoda lečenja obuhvaćeno je ukupno 42 nasumice izabrana, stabilna bolesnika (26 muškaraca i 16 žena) lečena primenom metode KAPD tokom poslednjih 12 godina. Isključeni su bolesnici sa teškom anemijom (Hb  lt 10 g/L) i malignom bolešću. Pri tome, 21 (50%) bolesnika kontinuirano je lečeno bioinkompatibilnim rastvorom za KAPD (kiseli standardni rastvor - ANDY-disc; grupa KAPDB-1), dok je preostalih 21 bolesnik sve vreme bilo na biokompatibilnijem rastvoru za KAPD (neutralni rastvor sa znatno manjom koncentracijom degradacionih produkata glukoze, 1.25 mmol/L Ca i 40 mmol/L laktata - Gambrosol Trio; grupa KAPDB-2). Svim bolesnicima određeni su odabrani parametri hronične inflamacije, malnutricije i ateroskleroze zajedno sa transportnim karakteristikama peritoneumske membrane i rezidualnom bubrežnom funkcijom nakon 2,5 ± 0,6 god od započinjanja KAPD. Svi dobijeni rezultati analizirani su kao potencijalni faktori rizika. Rezultati. Grupa KAPDB-2 u odnosu na KAPDB-1 imala je statistički značajno niže vrednosti serumskog hs-CRP (p = 0,003) i bolje parametre nutritivnog statusa izražene kroz obim nadlaktice (p = 0,015), obim mišića nadlaktice (p = 0,002) i subjektivnu globalnu procenu (p = 0,000) kao i u manjoj meri prisutnu aterosklerozu potvrđeno debljinom intimomedijalnog kompleksa (IMT) (p = 0,003), stepenom suženja karotida (p = 0,001) i prisustvom kalcifikovanih ateromatoznih plakova na karotidnim arterijama (p = 0,008). Kaplan-Meier-ova kriva preživljavanja potvrdila je značajno duže preživljavanje bolesnika u grupi KAPD-2 u odnosu na KAPDB-1 (1-, 5-, i 10-godišnje preživljavanje bolesnika iznosilo je redom: 100%, 61.9% i 14.3% u KAPDB-1, a 100%, 85,7% i 52,4% u KAPDB-2 grupi; p = 0,0345). Stopa 1-, 5-, i 10-godišnjeg preživljavanja metode iznosila je: 100%, 71,4% i 38,1% u KAPDB-1, a 100%, 85,7% i 76,2% u KAPDB-2 grupi (p = 0,0719). Kao nezavisni prediktori opšteg preživljavanja bolesnika na KAPD izdvojili su se: dijalizni staž, nivo serumskih triglicerida i skor kardiovaskularnog morbiditeta (kvantitativni sistem zbrajanja prisutnih sledećih parametara: ejekciona frakcija (EF) leve komore  lt  50%; IMT >1 mm; suženje lumena karotida > 50%; kalcifikovani ateromatozni plakovi na obe karotide; ishemijska bolest srca; cerebrovaskularni događaj i periferna vaskularna bolest sa ili bez gangrene). Kao nezavisan prediktor preživljavanja metode izdvojio se jedino dijalizni staž. Zaključak. Iako su bolesnici na KAPD sa biokompatibilnijim rastvorima pokazali statistički značajno bolje preživljavanje, ne možemo tvrditi da bioinkompatibilnost dijaliznih rastvora predstavlja značajan faktor rizika od preživljavanja bolesnika i same metode lečenja. Naime, multivarijantnom analizom kao prediktori opšteg preživljavanja bolesnika izdvojili su se samo dijalizni staž, nivo serumskih triglicerida i skor kardiovaskularnog morbiditeta, dok se za očuvanje peritoneumske membrane kao nezavisan faktor rizika prikazao samo dijalizni staž.",
publisher = "Vojnomedicinska akademija - Institut za naučne informacije, Beograd",
journal = "Vojnosanitetski pregled",
title = "Influence of peritoneal dialysis solution biocompatibility on long-term survival of patients on continuous ambulatory peritoneal dialysis and the technique itself, Uticaj biokompatibilnosti rastvora za peritoneumsku dijalizu na višegodišnje preživljavanje bolesnika na kontinuiranoj ambulantnoj peritoneumskoj dijalizi i same metode lečenja",
volume = "70",
number = "4",
pages = "352-362",
doi = "10.2298/VSP1304352S"
}

Stanković-Popović, V., Popović, D., Dimković, N., Maksić, Đ., Vasilijić, S., Čolić, M., Vučinić, Ž., Rađen, S.,& Miličić, B.. (2013). Influence of peritoneal dialysis solution biocompatibility on long-term survival of patients on continuous ambulatory peritoneal dialysis and the technique itself. in Vojnosanitetski pregled
Vojnomedicinska akademija - Institut za naučne informacije, Beograd., 70(4), 352-362.
https://doi.org/10.2298/VSP1304352S

Stanković-Popović V, Popović D, Dimković N, Maksić Đ, Vasilijić S, Čolić M, Vučinić Ž, Rađen S, Miličić B. Influence of peritoneal dialysis solution biocompatibility on long-term survival of patients on continuous ambulatory peritoneal dialysis and the technique itself. in Vojnosanitetski pregled. 2013;70(4):352-362.
doi:10.2298/VSP1304352S .

Stanković-Popović, Verica, Popović, Dragan, Dimković, Nada, Maksić, Đoko, Vasilijić, Saša, Čolić, Miodrag, Vučinić, Žarko, Rađen, Slavica, Miličić, Biljana, "Influence of peritoneal dialysis solution biocompatibility on long-term survival of patients on continuous ambulatory peritoneal dialysis and the technique itself" in Vojnosanitetski pregled, 70, no. 4 (2013):352-362,
https://doi.org/10.2298/VSP1304352S . .

TY  - JOUR
AU  - Stanković-Popović, Verica
AU  - Nesić, V.
AU  - Popović, D.
AU  - Maksić, Đoko
AU  - Čolić, Miodrag
AU  - Vasilijić, Saša
AU  - Vučinić, Žarko
AU  - Miličić, Biljana
AU  - Rađen, Slavica
AU  - Dimković, Nada
PY  - 2011
UR  - https://smile.stomf.bg.ac.rs/handle/123456789/1614
AB  - Background: Chronic inflammation, malnutrition and atherosclerosis (MIA syndrome) are important predictors of high mortality in continuous ambulatory peritoneal dialysis (CAPD) patients. We aimed to evaluate the effects of PD solutions (standard vs. biocompatible) on some parameters of MIA syndrome in patients undergoing CAPD. Methods: 42 stable patients who were on CAPD at least 2.5 years participated in this cross-sectional study. Patients who had severe anemia (Hb  lt  10 g/l), immunomodulatory therapy, peritonitis or any inflammatory conditions for at least 3 months before the analysis, malignant disease and acute exacerbation of heart failure, were excluded. 21 (50%) patients were treated with standard PD solutions (CAPDP-1), while the remaining 21(50% of patients) were treated with biocompatible PD solutions (neutral solutions with lower level of glucose degradation products and lower concentration of calcium, CAPDP-2). All patients underwent echocardiography and B-mode ultrasonography of common carotid arteries together with assessments of nutrition status and parameters of systemic and local inflammation. Results: There were no significant differences between the groups concerning age, gender, underlying disease, residual renal function, peritoneal transport characteristics, comorbidity or therapy applied. Patients from group CAPDP-2 had a significantly lower serum level of hs-CRP (3.7 +/- 2.6 mg/l vs. 6.3 +/- 4.5 mg/l; p = 0.023) and significantly better nutritional status confirmed by mid-arm circumference (p = 0.015), mid-arm muscle circumference (p = 0.002) and subjective global assessment (14.28% of patients in CAPDP-2 vs. 71% of patients in CAPDP-1 were malnourished; p = 0.000). Group CAPD-2 had less frequent left ventricular hypertrophy (p = 0.039), thinner intima-media thickness (p = 0.005), smaller carotid narrowing (p = 0.000) and fewer calcified plaques of common carotide arteries (p = 0.003). No significant difference between the CAPDP groups was observed in serum and effluent levels of inflammatory cytokines (IL-1, IL-6 and TNF-alpha) and CA-125 effluent level. Logistic regression analysis did not confirm that biocompatibility of PD solutions was an independent predictor of any parameter of MIA syndrome. Conclusions: According to the present study and logistic regression analysis, the effect of biocompatible CAPD solutions on parameters of malnutrition, inflammation and atherosclerosis have to be confirmed by well-designed and controlled studies in a higher number of patients.
PB  - Dustri-Verlag Dr Karl Feistle, Deisenhofen-Muenchen
T2  - Clinical Nephrology
T1  - Effects of conventional versus biocompatible peritoneal dialysis solutions on peritoneal and systemic inflammation, malnutrition and atherosclerosis in CAPD patients
VL  - 76
IS  - 4
SP  - 314
EP  - 322
DO  - 10.5414/CN106991
ER  - 

@article{
author = "Stanković-Popović, Verica and Nesić, V. and Popović, D. and Maksić, Đoko and Čolić, Miodrag and Vasilijić, Saša and Vučinić, Žarko and Miličić, Biljana and Rađen, Slavica and Dimković, Nada",
year = "2011",
abstract = "Background: Chronic inflammation, malnutrition and atherosclerosis (MIA syndrome) are important predictors of high mortality in continuous ambulatory peritoneal dialysis (CAPD) patients. We aimed to evaluate the effects of PD solutions (standard vs. biocompatible) on some parameters of MIA syndrome in patients undergoing CAPD. Methods: 42 stable patients who were on CAPD at least 2.5 years participated in this cross-sectional study. Patients who had severe anemia (Hb  lt  10 g/l), immunomodulatory therapy, peritonitis or any inflammatory conditions for at least 3 months before the analysis, malignant disease and acute exacerbation of heart failure, were excluded. 21 (50%) patients were treated with standard PD solutions (CAPDP-1), while the remaining 21(50% of patients) were treated with biocompatible PD solutions (neutral solutions with lower level of glucose degradation products and lower concentration of calcium, CAPDP-2). All patients underwent echocardiography and B-mode ultrasonography of common carotid arteries together with assessments of nutrition status and parameters of systemic and local inflammation. Results: There were no significant differences between the groups concerning age, gender, underlying disease, residual renal function, peritoneal transport characteristics, comorbidity or therapy applied. Patients from group CAPDP-2 had a significantly lower serum level of hs-CRP (3.7 +/- 2.6 mg/l vs. 6.3 +/- 4.5 mg/l; p = 0.023) and significantly better nutritional status confirmed by mid-arm circumference (p = 0.015), mid-arm muscle circumference (p = 0.002) and subjective global assessment (14.28% of patients in CAPDP-2 vs. 71% of patients in CAPDP-1 were malnourished; p = 0.000). Group CAPD-2 had less frequent left ventricular hypertrophy (p = 0.039), thinner intima-media thickness (p = 0.005), smaller carotid narrowing (p = 0.000) and fewer calcified plaques of common carotide arteries (p = 0.003). No significant difference between the CAPDP groups was observed in serum and effluent levels of inflammatory cytokines (IL-1, IL-6 and TNF-alpha) and CA-125 effluent level. Logistic regression analysis did not confirm that biocompatibility of PD solutions was an independent predictor of any parameter of MIA syndrome. Conclusions: According to the present study and logistic regression analysis, the effect of biocompatible CAPD solutions on parameters of malnutrition, inflammation and atherosclerosis have to be confirmed by well-designed and controlled studies in a higher number of patients.",
publisher = "Dustri-Verlag Dr Karl Feistle, Deisenhofen-Muenchen",
journal = "Clinical Nephrology",
title = "Effects of conventional versus biocompatible peritoneal dialysis solutions on peritoneal and systemic inflammation, malnutrition and atherosclerosis in CAPD patients",
volume = "76",
number = "4",
pages = "314-322",
doi = "10.5414/CN106991"
}

Stanković-Popović, V., Nesić, V., Popović, D., Maksić, Đ., Čolić, M., Vasilijić, S., Vučinić, Ž., Miličić, B., Rađen, S.,& Dimković, N.. (2011). Effects of conventional versus biocompatible peritoneal dialysis solutions on peritoneal and systemic inflammation, malnutrition and atherosclerosis in CAPD patients. in Clinical Nephrology
Dustri-Verlag Dr Karl Feistle, Deisenhofen-Muenchen., 76(4), 314-322.
https://doi.org/10.5414/CN106991

Stanković-Popović V, Nesić V, Popović D, Maksić Đ, Čolić M, Vasilijić S, Vučinić Ž, Miličić B, Rađen S, Dimković N. Effects of conventional versus biocompatible peritoneal dialysis solutions on peritoneal and systemic inflammation, malnutrition and atherosclerosis in CAPD patients. in Clinical Nephrology. 2011;76(4):314-322.
doi:10.5414/CN106991 .

Stanković-Popović, Verica, Nesić, V., Popović, D., Maksić, Đoko, Čolić, Miodrag, Vasilijić, Saša, Vučinić, Žarko, Miličić, Biljana, Rađen, Slavica, Dimković, Nada, "Effects of conventional versus biocompatible peritoneal dialysis solutions on peritoneal and systemic inflammation, malnutrition and atherosclerosis in CAPD patients" in Clinical Nephrology, 76, no. 4 (2011):314-322,
https://doi.org/10.5414/CN106991 . .